Literature DB >> 12618436

Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA.

Dan-Sung C Cho1, Weidong Yang, Joshua T Lee, Ramin Shiekhattar, John M Murray, Kazuko Nishikura.   

Abstract

Adenosine deaminases acting on RNA (ADAR) convert adenosine residues into inosines in double-stranded RNA. Three vertebrate ADAR gene family members, ADAR1, ADAR2, and ADAR3, have been identified. The catalytic domain of all three ADAR gene family members is very similar to that of Escherichia coli cytidine deaminase and APOBEC-1. Homodimerization is essential for the enzyme activity of those cytidine deaminases. In this study, we investigated the formation of complexes between differentially epitope-tagged ADAR monomers by sequential affinity chromatography and size exclusion column chromatography. Both ADAR1 and ADAR2 form a stable enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form. No heterodimer complex formation among different ADAR gene family members was detected. Analysis of HeLa and mouse brain nuclear extracts suggested that endogenous ADAR1 and ADAR2 both form a homodimer complex. Interestingly, endogenous ADAR3 also appears to form a homodimer complex, indicating the presence of a brain-specific mechanism for ADAR3 dimerization. Homodimer formation may be necessary for ADAR to act as active deaminases. Analysis of dimer complexes consisting of one wild-type and one mutant monomer suggests functional interactions between the two subunits during site-selective RNA editing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618436     DOI: 10.1074/jbc.M213127200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  A transition state analogue for an RNA-editing reaction.

Authors:  Brittany L Haudenschild; Olena Maydanovych; Eduardo A Véliz; Mark R Macbeth; Brenda L Bass; Peter A Beal
Journal:  J Am Chem Soc       Date:  2004-09-15       Impact factor: 15.419

Review 2.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

3.  Extra double-stranded RNA binding domain (dsRBD) in a squid RNA editing enzyme confers resistance to high salt environment.

Authors:  Juan Pablo Palavicini; Rodrigo A Correa-Rojas; Joshua J C Rosenthal
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

Review 4.  Substitutional A-to-I RNA editing.

Authors:  Bjorn-Erik Wulff; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2010 Jul-Aug       Impact factor: 9.957

Review 5.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 6.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

7.  ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells.

Authors:  Weidong Yang; Qingde Wang; Kelly L Howell; Joshua T Lee; Dan-Sung C Cho; John M Murray; Kazuko Nishikura
Journal:  J Biol Chem       Date:  2004-11-19       Impact factor: 5.157

8.  Chromosomal storage of the RNA-editing enzyme ADAR1 in Xenopus oocytes.

Authors:  Nina B Sallacz; Michael F Jantsch
Journal:  Mol Biol Cell       Date:  2005-04-20       Impact factor: 4.138

9.  SUMO-1 modification alters ADAR1 editing activity.

Authors:  Joana M P Desterro; Liam P Keegan; Ellis Jaffray; Ron T Hay; Mary A O'Connell; Maria Carmo-Fonseca
Journal:  Mol Biol Cell       Date:  2005-08-24       Impact factor: 4.138

10.  Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding.

Authors:  Mark R Macbeth; Arunth T Lingam; Brenda L Bass
Journal:  RNA       Date:  2004-10       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.